Cancer - Werewolf Therapeutics, Inc.

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05479812

A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors

Drug

WTX-124

Condition

Malignant melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell cancer, urothelial cancer, microsatellite instabilityhigh or mismatch repair deficient cancer, microsatellite -instability high- or mismatch repair defici